Drug
Xl820
Xl820: highest development phase Phase 2, developed by Exelixis. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Exelixis
Trials
| Drug | Phase | Indication |
|---|---|---|
| XL820 NCT00570635 | Phase 2 | Gastrointestinal Stromal Tumors |
Latest
No recent events.
Follow Xl820 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.